These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17321636)

  • 1. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma.
    Semela D; Piguet AC; Kolev M; Schmitter K; Hlushchuk R; Djonov V; Stoupis C; Dufour JF
    J Hepatol; 2007 May; 46(5):840-8. PubMed ID: 17321636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
    Piguet AC; Semela D; Keogh A; Wilkens L; Stroka D; Stoupis C; St-Pierre MV; Dufour JF
    J Hepatol; 2008 Jul; 49(1):78-87. PubMed ID: 18486258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR inhibitors for hepatocellular cancer: a forward-moving target.
    Treiber G
    Expert Rev Anticancer Ther; 2009 Feb; 9(2):247-61. PubMed ID: 19192962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism.
    Xu Y; Wen Z; Xu Z
    Anticancer Res; 2009 Dec; 29(12):5103-9. PubMed ID: 20044623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
    Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.
    Jung KH; Zheng HM; Jeong Y; Choi MJ; Lee H; Hong SW; Lee HS; Son MK; Lee S; Hong S; Hong SS
    Cancer Lett; 2013 Jan; 328(1):176-87. PubMed ID: 22902995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
    Huynh H
    Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
    Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
    Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus inhibits human pancreatic carcinoma cell proliferation by a mechanism linked to the targeting of mTOR/HIF-1 alpha/VEGF signaling.
    Wang Y; Zhao Q; Ma S; Yang F; Gong Y; Ke C
    IUBMB Life; 2007 Nov; 59(11):717-21. PubMed ID: 17968710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
    Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
    Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors.
    Verheul HM; Salumbides B; Van Erp K; Hammers H; Qian DZ; Sanni T; Atadja P; Pili R
    Clin Cancer Res; 2008 Jun; 14(11):3589-97. PubMed ID: 18519793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells.
    Zhang T; Sun HC; Zhou HY; Luo JT; Zhang BL; Wang P; Wang L; Qin LX; Ren N; Ye SL; Li Q; Tang ZY
    Cancer Lett; 2010 Apr; 290(2):204-10. PubMed ID: 19822391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
    Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
    Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of octreotide on angiogenesis induced by hepatocellular carcinoma in vivo.
    Jia WD; Xu GL; Sun HC; Wang L; Xu RN; Xue Q
    Hepatobiliary Pancreat Dis Int; 2003 Aug; 2(3):404-9. PubMed ID: 14599948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
    Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.
    Raskopf E; Vogt A; Sauerbruch T; Schmitz V
    J Hepatol; 2008 Dec; 49(6):977-84. PubMed ID: 18845354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mTOR suppresses experimental liver tumours.
    Rizell M; Lindner P
    Anticancer Res; 2005; 25(2A):789-93. PubMed ID: 15868910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.